All Stories

  1. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome
  2. Including diverse and admixed populations in genetic epidemiology research
  3. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites
  4. Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19
  5. Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof‐of‐concept study
  6. Gender matters in heart attack prevention: higher femininity linked to angina diagnosis in men
  7. Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation
  8. A sex-specific evolutionary interaction between ADCY9 and CETP
  9. Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
  10. The genomics of heart failure: design and rationale of the HERMES consortium
  11. Multitrait GWAS to connect disease variants and biological mechanisms
  12. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
  13. Genetics of symptom remission in outpatients with COVID-19
  14. A sex-specific evolutionary interaction betweenADCY9andCETP
  15. Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
  16. Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT
  17. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib
  18. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality
  19. ExPheWas: a browser for gene-based pheWAS associations
  20. Genetics of symptom remission in outpatients with COVID-19
  21. Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women
  22. Comparative effectiveness and safety of high‐dose rivaroxaban and apixaban for atrial fibrillation: A propensity score‐matched cohort study
  23. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect
  24. The associations of hostility and defensiveness with telomere length are influenced by sex and health status
  25. A genetic association study of heart failure: more evidence for the role of BAG3 in idiopathic dilated cardiomyopathy
  26. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
  27. Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure
  28. Statin Initiation: Guideline Concordance and Characteristics of New Users in Quebec, Canada
  29. A genetic model of ivabradine recapitulates results from randomized clinical trials
  30. Multitrait genetic-phenotype associations to connect disease variants and biological mechanisms
  31. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential
  32. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
  33. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta‐analysis
  34. Heritability of 596 lipid species and genetic correlation with cardiovascular traits in the Busselton Family Heart Study
  35. Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA‐HF trial
  36. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib
  37. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
  38. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation
  39. Inherited Chromosomally Integrated Human Herpesvirus 6 Demonstrates Tissue-Specific RNA Expression In Vivo That Correlates with an Increased Antibody Immune Response
  40. Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes
  41. rs73185306 C/T Is Not a Predisposing Risk Factor for Inherited Chromosomally Integrated Human Herpesvirus 6A/B
  42. Inherited chromosomally integrated HHV-6 demonstrates tissue-specific RNA expressionin vivothat correlates with increased antibody immune response
  43. Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
  44. Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians
  45. Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events
  46. Subsequent Event Risk in Individuals With Established Coronary Heart Disease
  47. Lipoprotein (a), arterial inflammation, and PCSK9 inhibition
  48. Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution
  49. Validation of genome-wide polygenic risk scores for coronary artery disease in French Canadians
  50. Biomarkers of dementia in obstructive sleep apnea
  51. Pharmacogenetic content of commercial genome-wide genotyping arrays
  52. Randomized Clinical Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific ADCY9 Genotype
  53. Variants at the APOE/C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High‐Density Lipoprotein Cholesterol
  54. Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A
  55. Protein-Coding Variants Implicate Novel Genes Related to Lipid Homeostasis Contributing to Body Fat Distribution
  56. Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines
  57. Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study
  58. Pharmacogenomics of blood lipid regulation
  59. A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure
  60. A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention
  61. Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort
  62. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
  63. Polygenic determinants in extremes of high-density lipoprotein cholesterol
  64. Exome-wide association study of plasma lipids in >300,000 individuals
  65. Precision medicine to change the landscape of cardiovascular drug development
  66. Impact of Selection Bias on Estimation of Subsequent Event Risk
  67. Identification of the genetic determinants responsible for retinal degeneration in families of Mexican descent
  68. Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies
  69. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions
  70. CKing Precision in the Interpretation of Diagnostic Biomarkers
  71. Diagnosis, Prevalence, Awareness, Treatment, Prevention, and Control of Hypertension in Cameroon: Protocol for a Systematic Review and Meta-Analysis of Clinic-Based and Community-Based Studies
  72. Protein-altering and regulatory genetic variants near GATA4 implicated in bicuspid aortic valve
  73. CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction
  74. Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol
  75. CETP
  76. Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease
  77. Pharmacogenomic approaches to lipid-regulating trials
  78. Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically
  79. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality
  80. Paternal Age Explains a Major Portion of De Novo Germline Mutation Rate Variability in Healthy Individuals
  81. A model to assess the cost–effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine
  82. Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population
  83. Meta-analysis of genome-wide association studies of HDL cholesterol response to statins
  84. genipe: an automated genome-wide imputation pipeline with automatic reporting and statistical tools
  85. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation
  86. Whole-genome sequencing in French Canadians from Quebec
  87. Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits
  88. Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals
  89. DNA methylation signature of human fetal alcohol spectrum disorder
  90. Avoidance of Vitamin K−Rich Foods Is Common among Warfarin Users and Translates into Lower Usual Vitamin K Intakes
  91. Pillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users
  92. Methylomic changes during conversion to psychosis
  93. Coding Variation inANGPTL4,LPL,andSVEP1and the Risk of Coronary Disease
  94. A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials
  95. An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance
  96. Testing the role of predicted gene knockouts in human anthropometric trait variation
  97. Resting heart rate as a predictor of aortic valve stenosis progression
  98. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease
  99. Calcium Signaling Pathway GenesRUNX2andCACNA1CAre Associated With Calcific Aortic Valve DiseaseCLINICAL PERSPECTIVE
  100. Will personalized drugs for cardiovascular disease become an option? – Defining ‘Evidence-based personalized medicine’ for its implementation and future use
  101. Impact of regular physical activity on weekly warfarin dose requirement
  102. Mutation Burden of Rare Variants in Schizophrenia Candidate Genes
  103. Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review
  104. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice
  105. Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
  106. Comparison of Sequencing Based CNV Discovery Methods Using Monozygotic Twin Quartets
  107. CKM and LILRB5 Are Associated With Serum Levels of Creatine Kinase
  108. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
  109. Genetic Markers of Cisplatin-Induced Hearing Loss in Children
  110. Modifiers of (CAG)n instability in Machado–Joseph disease (MJD/SCA3) transmissions: an association study with DNA replication, repair and recombination genes
  111. Development of a broad-based ADME panel for use in pharmacogenomic studies
  112. Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis
  113. Novel presenilin mutations within Moroccan patients with Early-Onset Alzheimer’s Disease
  114. Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits
  115. Novel Mutations in the Amyloid Precursor Protein Gene within Moroccan Patients with Alzheimer's Disease
  116. Comparison of genotype clustering tools with rare variants
  117. Cuckoo search epistasis: a new method for exploring significant genetic interactions
  118. Validation of patient-reported warfarin dose in a prospective incident cohort study
  119. Evaluation of Links Between High-Density Lipoprotein Genetics, Functionality, and Aortic Valve Stenosis Risk in Humans
  120. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity
  121. pyGenClean: efficient tool for genetic data clean up before association testing
  122. Erratum: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
  123. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
  124. Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children
  125. The Impact of Partial and Complete Loss-of-Function Mutations in Endothelial Lipase on High-Density Lipoprotein Levels and Functionality in Humans
  126. Institutional Profile: The Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre at the Montreal Heart Institute
  127. SRAP Polymorphisms Associated to Cell Wall Degradability in Lignified Stems of Alfalfa
  128. Pooled DNA Resequencing of 68 Myocardial Infarction Candidate Genes in French Canadians
  129. Rare Copy Number Variants Contribute to Congenital Left-Sided Heart Disease
  130. Genetic control of high density lipoprotein-cholesterol in AcB/BcA recombinant congenic strains of mice
  131. Segregation of LIPG, CETP, and GALNT2 Mutations in Caucasian Families with Extremely High HDL Cholesterol
  132. Assessment of Genetic Variability of Cell Wall Degradability for the Selection of Alfalfa with Improved Saccharification Efficiency
  133. PRKCB is associated with calcineurin inhibitor-induced renal dysfunction in heart transplant recipients
  134. Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
  135. Molecular physiology and breeding at the crossroads of cold hardiness improvement
  136. Risk of congenital heart defects is influenced by genetic variation in folate metabolism
  137. Erratum to: Intron-length polymorphism identifies a Y2K4 dehydrin variant linked to superior freezing tolerance in alfalfa
  138. Validation of warfarin pharmacogenetic algorithms in clinical practice
  139. Intron-length polymorphism identifies a Y2K4 dehydrin variant linked to superior freezing tolerance in alfalfa
  140. Design and rationale of a genetic cohort study on congenital cardiac disease: experiences from a multi-institutional platform in Quebec
  141. Predicting Statin Induced Muscle Toxicity
  142. Fetal Alcohol Spectrum Disorders: Gene-Environment Interactions, Predictive Biomarkers, and the Relationship Between Structural Alterations in the Brain and Functional Outcomes
  143. Familial ventricular aneurysms and septal defects map to chromosome 10p15
  144. Positional cloning of a quantitative trait locus contributing to pain sensitivity: possible mediation by Tyrp1
  145. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura
  146. Direct Measure of the De Novo Mutation Rate in Autism and Schizophrenia Cohorts
  147. Partitioning of copy-number genotypes in pedigrees
  148. Family Study of Restless Legs Syndrome in Quebec, Canada
  149. Mutations in DCC Cause Congenital Mirror Movements
  150. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia
  151. Genetic determinants of blood pressure reduction following potassium supplementation: and the candidates are…
  152. Genetics of bronchopulmonary dysplasia in the age of genomics
  153. Testing for Gene-Gene Interaction with AMMI Models
  154. Novel mutations in the sacsin gene in ataxia patients from Maritime Canada
  155. Genetic Studies
  156. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
  157. Genetic Modulation of Brugada Syndrome by a Common Polymorphism
  158. Application of principal component analysis to pharmacogenomic studies in Canada
  159. Association between cervical and intracranial dimensions and syringomyelia in the cavalier King Charles spaniel
  160. Mutation in Pyrroline-5-Carboxylate Reductase 1 Gene in Families with Cutis Laxa Type 2
  161. Application of Homozygosity Haplotype Analysis to Genetic Mapping with High-Density SNP Genotype Data
  162. Genetic predictors of depressive symptoms in cardiac patients
  163. The challenge of detecting epistasis (G×G Interactions): Genetic Analysis Workshop 16
  164. Autosomal-dominant locus for restless legs syndrome in French-Canadians on chromosome 16p12.1
  165. Génome Québec & Montreal Heart Institute Pharmacogenomics Centre: a translational pharmacogenomics platform – from R&D to the clinic
  166. Mutations in the calcium-related gene IL1RAPL1 are associated with autism
  167. A survey of the personalized medicine landscape
  168. Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan
  169. Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure
  170. A novel locus for idiopathic generalized epilepsy in French-Canadian families maps to 10p11
  171. No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans
  172. The Genetics of Congenital Amusia (Tone Deafness): A Family-Aggregation Study
  173. Mutations in the UBIAD1 Gene, Encoding a Potential Prenyltransferase, Are Causal for Schnyder Crystalline Corneal Dystrophy
  174. Syringomyelia in cavalier King Charles spaniels: the relationship between syrinx dimensions and pain
  175. Obesity and TCF7L2 variants' additive effect on type 2 diabetes risk in cardiac patients
  176. Molecular genetic studies of DMT1 on 12q in French‐Canadian restless legs syndrome patients and families
  177. Loss-of-function genetic diseases and the concept of pharmaceutical targets
  178. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations
  179. Lamin A/C mutations associated with familial and sporadic cases of dilated cardiomyopathy in Koreans
  180. Multistage designs in the genomic era: Providing balance in complex disease studies
  181. A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13
  182. Bootstrap Inference with Neural-Network Modeling for Gene-Disease Association Testing
  183. A new locus for autosomal dominant intracranial aneurysm, ANIB4, maps to chromosome 5p15.2-14.3
  184. Human monogenic disorders — a source of novel drug targets
  185. Common Genetic Vulnerability to Depressive Symptoms and Coronary Artery Disease: A Review and Development of Candidate Genes Related to Inflammation and Serotonin
  186. Autism spectrum disorders associated with X chromosome markers in French-Canadian males
  187. A Variant in XPNPEP2 Is Associated with Angioedema Induced by Angiotensin I–Converting Enzyme Inhibitors
  188. Analysis of microsatellite markers and single nucleotide polymorphisms in candidate genes for susceptibility to bipolar affective disorder in the chromosome 12Q24.31 region
  189. Chromosome 11-q24 region in Tourette syndrome: Association and linkage disequilibrium study in the French Canadian population
  190. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease
  191. The 14q restless legs syndrome locus in the French Canadian population
  192. Identification of a Novel Gene (HSN2) Causing Hereditary Sensory and Autonomic Neuropathy Type II through the Study of Canadian Genetic Isolates
  193. Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
  194. AnALS2gene mutation causes hereditary spastic paraplegia in a Pakistani kindred
  195. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy
  196. Fine mapping the candidate region for peripheral neuropathy with or without agenesis of the corpus callosum in the French Canadian population
  197. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives
  198. Clouston hidrotic ectodermal dysplasia (HED): genetic homogeneity, presence of a founder effect in the French Canadian population and fine genetic mapping
  199. Genomic structure of the human GT334 (EHOC-1) gene mapping to 21q22.3